DBV Technologies S.A. (DBVT): Price and Financial Metrics

DBV Technologies S.A. (DBVT): $0.75

0.02 (-2.30%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add DBVT to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#161 of 357

in industry

DBVT Price/Volume Stats

Current price $0.75 52-week high $2.37
Prev. close $0.77 52-week low $0.65
Day low $0.72 Volume 14,500
Day high $0.76 Avg. volume 50,689
50-day MA $0.84 Dividend yield N/A
200-day MA $1.19 Market Cap 144.47M

DBVT Stock Price Chart Interactive Chart >

DBVT POWR Grades

  • DBVT scores best on the Sentiment dimension, with a Sentiment rank ahead of 83.66% of US stocks.
  • DBVT's strongest trending metric is Growth; it's been moving up over the last 168 days.
  • DBVT's current lowest rank is in the Momentum metric (where it is better than 6.62% of US stocks).

DBVT Stock Summary

  • The ratio of debt to operating expenses for DBV TECHNOLOGIES SA is higher than it is for about just 5.51% of US stocks.
  • With a price/sales ratio of 30.53, DBV TECHNOLOGIES SA has a higher such ratio than 95.44% of stocks in our set.
  • As for revenue growth, note that DBVT's revenue has grown -38.88% over the past 12 months; that beats the revenue growth of merely 6.75% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to DBV TECHNOLOGIES SA, a group of peers worth examining would be BNTC, HYLN, CRDF, MRUS, and BOLT.
  • DBVT's SEC filings can be seen here. And to visit DBV TECHNOLOGIES SA's official web site, go to www.dbv-technologies.com.

DBVT Valuation Summary

  • DBVT's price/sales ratio is 33.1; this is 1404.55% higher than that of the median Healthcare stock.
  • Over the past 112 months, DBVT's price/sales ratio has gone down 164.1.

Below are key valuation metrics over time for DBVT.

Stock Date P/S P/B P/E EV/EBIT
DBVT 2023-12-29 33.1 1.3 -1.8 -0.4
DBVT 2023-12-28 34.4 1.3 -1.9 -0.4
DBVT 2023-12-27 36.1 1.4 -2.0 -0.5
DBVT 2023-12-26 32.9 1.3 -1.8 -0.4
DBVT 2023-12-22 32.0 1.2 -1.8 -0.3
DBVT 2023-12-21 31.9 1.2 -1.8 -0.3

DBV Technologies S.A. (DBVT) Company Bio


DBV Technologies SA has developed a proprietary, patented technology for administering an allergen to intact skin while avoiding transfer to the blood, and thus lowering the risk of a systemic, allergic reaction in the event of accidental exposure. DBV Technologies is focusing on food allergies, including milk and peanut, for which there are currently no effective treatments. The company was founded in 2002 and is based in Bagneux, France.


DBVT Latest News Stream


Event/Time News Detail
Loading, please wait...

DBVT Latest Social Stream


Loading social stream, please wait...

View Full DBVT Social Stream

Latest DBVT News From Around the Web

Below are the latest news stories about DBV TECHNOLOGIES SA that investors may wish to consider to help them evaluate DBVT as an investment opportunity.

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023

Information regarding the total number of voting rights and total number of shares of the Company as of November 30, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights11/30/2023 96,431,770 Total gross of voting rights: 96,431,770 Total net* of voting rights: 96,186,256 * Net total = total number of voting rights attached to shares – shares without v

Yahoo | December 4, 2023

DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers

Montrouge, France, November 9, 2023 DBV Technologies Announces 2-Year Results from Ongoing Phase 3 Open-Label Extension to the EPITOPE Trial (EPOPEX) of Viaskin™ Peanut in Toddlers Viaskin Peanut showed improvement between months 12 and 24 of treatment across all efficacy parameters. Notably, 81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.55.9% of subjects completed the oral food challenge at a cumulative dose of 3,444

Yahoo | November 9, 2023

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2023 (Article 223-16 of the General Regulations of the Autorité des Marchés Financiers) Market : NYSE Euronext Paris ISIN Code: FR 0010417345 Date Total number of shares Total number of voting rights 10/31/2023 96,288,553 Total gross of voting rights: 96,288,553 Total net* of voting rights: 96,084,083 * Net total = total number of voting rights attached to shares – shares w

Yahoo | November 6, 2023

DBV Technologies to Present New Data at ACAAI 2023

Montrouge, France, November 2, 2023 DBV Technologies to Present New Data at ACAAI 2023 New data to include late-breaking abstract detailing interim 12-month results from the ongoing Phase 3 open-label extension to the EPITOPE trial (EPOPEX) of Viaskin™ Peanut in peanut-allergic toddlers. DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced that new data on the use of Viaskin™ Peanut (DBV712) 250 μg in peanu

Yahoo | November 2, 2023

DBV Technologies S.A. (NASDAQ:DBVT) Q3 2023 Earnings Call Transcript

DBV Technologies S.A. (NASDAQ:DBVT) Q3 2023 Earnings Call Transcript October 31, 2023 DBV Technologies S.A. misses on earnings expectations. Reported EPS is $-0.1742 EPS, expectations were $-0.15. Operator: Welcome to the DBV’s Third Quarter Financial Results and Business and Regulatory Update Conference Call. [Operator Instructions] Please note this event is being recorded. I would now […]

Yahoo | November 1, 2023

Read More 'DBVT' Stories Here

DBVT Price Returns

1-mo -6.68%
3-mo -21.28%
6-mo -44.85%
1-year -54.82%
3-year -86.06%
5-year -90.27%
YTD -21.28%
2023 -37.73%
2022 -4.38%
2021 -38.93%
2020 -75.51%
2019 66.67%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!